Compare Novartis with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs LUPIN - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS LUPIN NOVARTIS/
LUPIN
 
P/E (TTM) x 493.9 47.5 1,040.6% View Chart
P/BV x 28.7 2.4 1,177.4% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 NOVARTIS   LUPIN
EQUITY SHARE DATA
    NOVARTIS
Mar-18
LUPIN
Mar-19
NOVARTIS/
LUPIN
5-Yr Chart
Click to enlarge
High Rs758986 76.9%   
Low Rs579720 80.4%   
Sales per share (Unadj.) Rs228.4369.5 61.8%  
Earnings per share (Unadj.) Rs31.713.4 236.8%  
Cash flow per share (Unadj.) Rs32.837.4 87.6%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.1303.7 97.8%  
Shares outstanding (eoy) m24.69452.49 5.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.3 126.8%   
Avg P/E ratio x21.163.6 33.1%  
P/CF ratio (eoy) x20.422.8 89.4%  
Price / Book Value ratio x2.22.8 80.1%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,505386,064 4.3%   
No. of employees `0000.717.7 3.8%   
Total wages/salary Rs m1,44531,513 4.6%   
Avg. sales/employee Rs Th8,441.39,453.8 89.3%   
Avg. wages/employee Rs Th2,163.61,782.0 121.4%   
Avg. net profit/employee Rs Th1,173.1343.0 342.0%   
INCOME DATA
Net Sales Rs m5,639167,182 3.4%  
Other income Rs m1,7183,640 47.2%   
Total revenues Rs m7,357170,822 4.3%   
Gross profit Rs m-6328,822 -0.2%  
Depreciation Rs m2510,850 0.2%   
Interest Rs m553,078 1.8%   
Profit before tax Rs m1,57518,534 8.5%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m7929,017 8.8%   
Profit after tax Rs m7846,066 12.9%  
Gross profit margin %-1.117.2 -6.4%  
Effective tax rate %50.348.7 103.3%   
Net profit margin %13.93.6 383.0%  
BALANCE SHEET DATA
Current assets Rs m9,522138,536 6.9%   
Current liabilities Rs m3,29661,299 5.4%   
Net working cap to sales %110.446.2 239.0%  
Current ratio x2.92.3 127.8%  
Inventory Days Days3784 43.7%  
Debtors Days Days28112 25.3%  
Net fixed assets Rs m46127,516 0.0%   
Share capital Rs m123905 13.6%   
"Free" reserves Rs m7,213136,517 5.3%   
Net worth Rs m7,336137,422 5.3%   
Long term debt Rs m066,417 0.0%   
Total assets Rs m11,105279,494 4.0%  
Interest coverage x29.57.0 420.0%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.50.6 84.9%   
Return on assets %7.63.3 230.9%  
Return on equity %10.74.4 242.0%  
Return on capital %22.28.9 249.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6159,414 0.1%   
Fx outflow Rs m3,63022,282 16.3%   
Net fx Rs m-3,57037,132 -9.6%   
CASH FLOW
From Operations Rs m1,61016,660 9.7%  
From Investments Rs m687-32,825 -2.1%  
From Financial Activity Rs m-2,6777,441 -36.0%  
Net Cashflow Rs m-380-8,724 4.4%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 75.0 0.2 37,500.0%  
Indian inst/Mut Fund % 2.0 11.3 17.7%  
FIIs % 1.6 31.9 5.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.1 212.9%  
Shareholders   41,647 98,259 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS